Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPX4 | P36969 | 8/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788388 | 1.00 | GPX4 (0.49) | GPX4LMNANPSR1MAPTNPC1 | |
| SCHEMBL14788496 | 0.91 | GPX4 (0.49) | GPX4LMNANPSR1MAPTNPC1 | |
| SCHEMBL29172532 | 0.90 | GPX4 (0.43) | GPX4LMNANPSR1MAPTNPC1 | |
| SCHEMBL14788390 | 0.89 | GPX4 (0.54) | GPX4LMNANPSR1MAPTNPC1 | |
| SCHEMBL14788457 | 0.86 | C5AR1 (0.45) | MAPTSMN1; SMN2ALDH1A1TP53C5AR1 | |
| SCHEMBL27264728 | 0.84 | GPX4 (0.70) | GPX4LMNANPSR1MAPTNPC1 | |
| SCHEMBL12639686 | 0.80 | POLB (0.53) | GPX4LMNANPSR1MAPTYAP1 | |
| SCHEMBL14788327 | 0.79 | LMNA (0.47) | GPX4LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14788385 | 0.77 | CYP1A2 (0.49) | GPX4LMNANPSR1MAPTYAP1 | |
| SCHEMBL14788325 | 0.76 | ALDH1A1 (0.46) | LMNAMAPTSMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118340891-A | Application of PDI inhibitor in preparation of product for inhibiting STING activation | 暨南大学附属第一医院（广州华侨医院） | 2024-07-16 | — | — | CN | claimed |
| US-20240216365-A1 | METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-07-04 | — | — | US | claimed |
| US-11883459-B2 | Thiol isomerases inhibitors for the treatment and prevention of food allergies, allergic diseases, and inflammatory diseases | WESTERN NEW ENGLAND UNIVERSITY (US) | 2024-01-30 | — | — | US | claimed |
| US-11883395-B2 | Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-01-30 | — | — | US | claimed |
| CN-117379403-A | Use of substances that reduce PDI activity in the treatment of autoimmune diseases | 北京大学 | 2024-01-12 | — | — | CN | claimed |
| CN-115057909-A | Protein degradation targeting chimera based on compound PACMA31, and preparation method and application thereof | 浙江工业大学 | 2022-09-16 | — | — | CN | claimed |
| US-20260130924-A1 | COMPOSITIONS AND METHODS OF TREATING SUBJECTS WITH BRCA1 MUTATION OR DEFICIENCY | UNIV TEXAS (US) | 2026-05-14 | — | — | US | disclosed |
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | ACADEMIA SINICA (TW) | 2026-04-21 | — | — | US | disclosed |
| EP-4069252-B1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING SS-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (CN) | 2025-12-10 | — | — | EP | disclosed |
| EP-4573078-A1 | THIOL ISOMERASES INHIBITORS; PREPARATION THEREOF; AND METHODS OF USE THEREOF | Western New England University (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | LIFECEUTIX CO., LTD. (KR) | 2025-04-03 | — | — | US | disclosed |
| WO-2025029660-A9 | COMPOUNDS WITH SELECTIVITY FOR CERTAIN CANCERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025029660-A1 | COMPOUNDS WITH SELECTIVITY FOR CERTAIN CANCERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-02-06 | — | — | WO | disclosed |
| US-11883395-B2 | Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-01-30 | — | — | US | disclosed |
| CN-117379403-A | Use of substances that reduce PDI activity in the treatment of autoimmune diseases | 北京大学 | 2024-01-12 | — | — | CN | disclosed |
| CN-117379403-A | Use of substances that reduce PDI activity in the treatment of autoimmune diseases | 北京大学 | 2024-01-12 | — | — | CN | disclosed |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | ACADEMIA SINICA (TW) | 2023-02-16 | — | — | US | disclosed |
| CN-115057909-A | Protein degradation targeting chimera based on compound PACMA31, and preparation method and application thereof | 浙江工业大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-115057909-A | Protein degradation targeting chimera based on compound PACMA31, and preparation method and application thereof | 浙江工业大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-115057909-A | Protein degradation targeting chimera based on compound PACMA31, and preparation method and application thereof | 浙江工业大学 | 2022-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883395-B2 | Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor | PDIA3, PDIA5, PDIA4 | GPX4 70/4885LMNA 4379/4885NPSR1 2421/4885 |
| US-11883459-B2 | Thiol isomerases inhibitors for the treatment and prevention of food allergies, allergic diseases, and inflammatory diseases | SERPINB1, PPIE, TST | GPX4 156/4885LMNA 4716/4885NPSR1 3326/4885 |
| US-12605353-B2 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | PDIA4, PDIA5, PDIA6 | GPX4 144/4885LMNA 3889/4885NPSR1 4320/4885 |
| US-20260130924-A1 | COMPOSITIONS AND METHODS OF TREATING SUBJECTS WITH BRCA1 MUTATION OR DEFICIENCY | BRCA1, GPX4, GPX1 | GPX4 2/4885LMNA 2661/4885NPSR1 4270/4885 |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | GLA, LIMS1, TP53 | GPX4 215/4885LMNA 25/4885NPSR1 4225/4885 |
| US-20230046445-A1 | PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ß-CELL PATHOGENESIS AND TREATING DIABETES | PDIA4, PDIA6, PDIA5 | GPX4 39/4885LMNA 4016/4885NPSR1 3934/4885 |
| US-20240216365-A1 | METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS | PDIA3, PDIA4, PDIA5 | GPX4 65/4885LMNA 4086/4885NPSR1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.